76 related articles for article (PubMed ID: 12529735)
1. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
Brassard JA; Curtis BR; Cooper RA; Ferguson J; Komocsar W; Ehardt M; Kupfer S; Maurath C; Swabb E; Cannon CP; Aster RH
Thromb Haemost; 2002 Dec; 88(6):892-7. PubMed ID: 12529735
[TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
Abrams CS; Cines DB
Thromb Haemost; 2002 Dec; 88(6):888-9. PubMed ID: 12529733
[No Abstract] [Full Text] [Related]
3. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Scirica BM; Cannon CP; Cooper R; Aster RH; Brassard J; McCabe CH; Charlesworth A; Skene AM; Braunwald E
J Thromb Thrombolysis; 2006 Oct; 22(2):95-102. PubMed ID: 17008974
[TBL] [Abstract][Full Text] [Related]
4. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Cannon CP; McCabe CH; Wilcox RG; Langer A; Caspi A; Berink P; Lopez-Sendon J; Toman J; Charlesworth A; Anders RJ; Alexander JC; Skene A; Braunwald E
Circulation; 2000 Jul; 102(2):149-56. PubMed ID: 10889124
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
O'Connor FF; Shields DC; Fitzgerald A; Cannon CP; Braunwald E; Fitzgerald DJ
Blood; 2001 Dec; 98(12):3256-60. PubMed ID: 11719362
[TBL] [Abstract][Full Text] [Related]
6. Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
Dunkley S; Evans S; Gaudry L; Jepson N
Platelets; 2005 Dec; 16(8):462-8. PubMed ID: 16287613
[TBL] [Abstract][Full Text] [Related]
7. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes.
Serrano CV; Nicolau JC; Venturinelli M; Baracioli LM; Anders RJ; Cannon CP; Ramires JA
Cardiovasc Drugs Ther; 2003 Mar; 17(2):129-32. PubMed ID: 12975594
[TBL] [Abstract][Full Text] [Related]
8. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
[TBL] [Abstract][Full Text] [Related]
9. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
Nicholson NS; Abood NA; Panzer-Knodle SG; Frederick LG; Page JD; Salyers AK; Suleymanov OD; Szalony JA; Taite BB; Anders RJ
Med Res Rev; 2001 May; 21(3):211-26. PubMed ID: 11301411
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.
O'Neill WW; Serruys P; Knudtson M; van Es GA; Timmis GC; van der Zwaan C; Kleiman J; Gong J; Roecker EB; Dreiling R; Alexander J; Anders R
N Engl J Med; 2000 May; 342(18):1316-24. PubMed ID: 10793164
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation.
Adderley SR; Fitzgerald DJ
J Biol Chem; 2000 Feb; 275(8):5760-6. PubMed ID: 10681563
[TBL] [Abstract][Full Text] [Related]
12. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Atar S; Cannon CP; Murphy SA; Rosanio S; Uretsky BF; Birnbaum Y
Am Heart J; 2006 May; 151(5):976.e1-6. PubMed ID: 16644315
[TBL] [Abstract][Full Text] [Related]
13. Platelet-associated anti-glycoprotein (GP) IIb-IIIa autoantibodies in chronic immune thrombocytopenic purpura mainly recognize cation-dependent conformations: comparison with the epitopes of serum autoantibodies.
Kosugi S; Tomiyama Y; Shiraga M; Kashiwagi H; Mizutani H; Kanakura Y; Kurata Y; Matsuzawa Y
Thromb Haemost; 1996 Feb; 75(2):339-45. PubMed ID: 8815587
[TBL] [Abstract][Full Text] [Related]
14. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis.
Kajihara M; Kato S; Okazaki Y; Kawakami Y; Ishii H; Ikeda Y; Kuwana M
Hepatology; 2003 Jun; 37(6):1267-76. PubMed ID: 12774004
[TBL] [Abstract][Full Text] [Related]
15. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction.
Holmes MB; Sobel BE; Cannon CP; Schneider DJ
Am J Cardiol; 2000 Feb; 85(4):491-3, A10. PubMed ID: 10728957
[TBL] [Abstract][Full Text] [Related]
16. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced and drug-dependent immune thrombocytopenias.
Greinacher A; Eichler P; Lubenow N; Kiefel V
Rev Clin Exp Hematol; 2001 Sep; 5(3):166-200; discussion 311-2. PubMed ID: 11703814
[TBL] [Abstract][Full Text] [Related]
18. Xemilofiban/orbofiban: insight into drug development.
Anders R; Kleiman J; Nicholson N; Wazowicz B; Burns D
Cardiovasc Drug Rev; 2001; 19(2):116-32. PubMed ID: 11484066
[TBL] [Abstract][Full Text] [Related]
19. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus.
Kuwana M; Kaburaki J; Okazaki Y; Miyazaki H; Ikeda Y
Rheumatology (Oxford); 2006 Jul; 45(7):851-4. PubMed ID: 16418192
[TBL] [Abstract][Full Text] [Related]
20. Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction.
Attaya S; Kanthi Y; Aster R; McCrae K
Platelets; 2009 Feb; 20(1):64-7. PubMed ID: 19172524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
